L5 WBC Disorders Flashcards
Hodgkin Lymphoma
Characteristics
Age
Reed Sternberg cells w/ inflammatory infiltrate
Fever
Young adults (20-30) and old (50-)
Single limphnode or chain of lymphnodes
Reed Sternberg cell Size Nucleus Nucleoli Origin
Large cell
Mirror image nuclei
Prominent nucleoli
B lymphocyte origin
Other diseases with Reed Sternberg cells
Mono
Epstein Barr
Non Hodkin Lymphoma
Characteristics
Ages
Morphologically diverse
Multiple node involvment, extranodal spread, blood involvement
All ages
Non Hodkin Lymphoma
Origin
85% clonal neoplasms of B lymphocytes
15% T cell origin
B cells that have been arrested at a particular stage clonally proliferate
Hodkins spread
lyphnode
spleen
liver
bone marrow
Staging for hodkin lymphoma
I: Tumor in one anatomical region or two contiguous anatomic regions on same side of diaphragm
II: more than two anatomic regions or two NON contiguous regions on the same side???????
III: Tumor on both sides of diaphragm, not extending beyond lymph nodes, spleen or waldeyer’s ring
IV: tumor in bone marrow, lung, etc
A:Absent systemic
B: present systemic: fever, night sweats, weight loss
Non Hodkin lymphoma clinical features
Painless enlarged lymph nodes or liver and spleen spread
Types of leukemias
Acute lymphocytic
Chronic lymphocytic
Acute myelogenous
Chronic myelogenous
Acute vs chronic leukemias Course Peripheral blood White cell count Bone marrow
Acute: -Rapid, fatal in months -Mostly blasts (immature cells) -Increased. Decreased in 30% -More than 20% blasts Chronic -Indolent, years -mature cells -Increased -No increase in blasts
Acute lymphoblastic leukemia
Proliferating cell
Age group
Subtypes
Primitive lymphoid cell
Most frequent in under 15, peak at 4
Principal cause of childhood deaths
Early B, Pre-B, Mature B, T
Diagnosing AML
Auer rods (cytoplasmic inclusion)
Philadelphia chromosome
What does it do
Occurs in proliferating cells of Chronic Myelogenous Leukemia
Results in fusion of BCR-ABL gene, mimicking growth factor, driving proliferation
Blast crisis
increase in immature cells in blood and bone marrow
decreased response to treatment
1/3 lymphoid
2/3 myeloid (opposite of prevalence)
Initial therapy for blast crisis
Inhibitor of BCR-ABL tyrosine kinase